Time filter

Source Type

Thariat J.,University of Nice Sophia Antipolis | Thariat J.,French National Center for Scientific Research | Thariat J.,Center Antoine Lacassagne | Etienne-Grimaldi M.-C.,Center Antoine Lacassagne | And 18 more authors.
Clinical Cancer Research | Year: 2012

Purpose: Epidermal growth factor receptor (EGFR) overexpression is associated with poor prognosis in head and neck squamous cell carcinoma (HNSCC). Despite intensive biomarker studies, a consensual method for assessing EGFR protein expression is still lacking. Here we set out to compare three EGFR detection methods in tumor specimens from HNSCC patients. Experimental Design: Tumors were prospectively excised from a series of 79 high-risk HNSCC patients enrolled in a GORTEC-sponsored clinical trial. EGFR expression was determined using a ligand-binding assay on membranes, Western blotting (WB) on membranes and total homogenates, and immunohistochemistry (IHC) on tissue microarrays. In addition, phosphorylated EGFR (pEGFR) was measured by WB on membranes. Results: Distributions and ranges of tumor EGFR expression were method dependent. Moderate positive correlations (Spearman coefficient r ≈ 0.50) were observed between EGFR expression measured by the binding assay and WB or IHC. pEGFR levels positively and significantly correlated with total EGFR expression measured by WB or ligand binding, but not by IHC. The highest correlation (r = 0.85) was observed between EGFR and pEGFR levels, both measured by WB on membranes. Interestingly, the fraction of phosphorylated receptor (pEGFR/EGFR both measured by WB on membranes) significantly declined with increasing tumor EGFR expression, by all assessment methods used. Conclusion: This study shows significant correlations between EGFR detection methods. The observed relationships between EGFR and pEGFR indicate that high-throughput pEGFR/EGFR analyses merit further investigations and consideration for routine use in patient samples. ©2012 AACR.

Calvo F.A.,Hospital General Universitario | Calvo F.A.,Complutense University of Madrid | Sole C.V.,Institute Gustave Roussy Cancer Campus | Rivera S.,Institute Gustave Roussy Cancer Campus | And 9 more authors.
Clinical and Translational Oncology | Year: 2014

Age is an important feature at the time of early breast cancer diagnosis. Radiotherapy is a mandatory component of treatment for breast-conserving strategies in early disease stages. Breast radiotherapy has rapidly evolved in the last 20 years. A tendency to less treatment volume (partial-breast irradiation) and less treatment time (hypofractionation) is consolidated in modern radiation oncology practice. Age and risk for local recurrence guide the decision-making process to electro-optimal treatment. Radiotherapy technological versatility offers multiple options for individualized (risk-age adapted) recommendations. © 2014 Federación de Sociedades Españolas de Oncología (FESEO).

Simo M.,Hospital Universitari Of Bellvitge And Ico Duran ynals | Velasco R.,Hospital Universitari Of Bellvitge And Ico Duran ynals | Graus F.,Service of Neurology | Verger E.,Service of Radiation Oncology | And 4 more authors.
Journal of Neuro-Oncology | Year: 2012

Epilepsy in glioblastoma multiforme (GBM) patients is common. Hematological toxicity is a potential side effect of antiepileptic drugs (AEDs) and a frequent limiting-dose effect of temozolomide (TMZ). The aim of the study was to investigate the impact of AEDs on thrombocytopenia in GBM patients treated with radiotherapy and TMZ. A cohort of 101 newly diagnosed GBM patients treated with radiotherapy and TMZ was reviewed. Clinical data, presence of seizures, AEDs use, platelet count, and accumulated TMZ dose were analyzed at each cycle. Thrombocytopenia was operationalized as a continuous platelet count and a dichotomic variable (cut-off\100.000/ mm3). This cut-off represents the threshold beyond which TMZ treatment is modified. A linear and a probit pooled cross-sectional regression analysis were used to study the impact of age, gender, AEDs, and accumulated TMZ on thrombocytopenia. Impact of AEDs on survival was also analyzed. Thirty-five patients (35%) presented seizures at onset and 18 (27%) during follow-up. Seven (13%) needed two or more AEDs for seizure control. Grade 3-4 thrombocytopenia was found in 8%. Decrease in platelet count was related to accumulated TMZ (p\0.001), age (p\0.001), and valproate (p = 0.004). Platelet count \100.000/mm3 was only associated with accumulated TMZ (p = 0.001). Recursive Partitioning Analysis prognostic class was the only variable with significant impact on survival. Valproate and age had an independent negative effect on total platelet count, although neither had an effect on critical thrombocytopenia (\100.000/mm3). Therefore, the systematic withhold of valproate inGBMpatients might not be justified. Nevertheless, this negative effect may be taken into account especially in elderly patients. © 2012 Springer Science+Business Media, LLC.

Calvo F.A.,Hospital General Universitario Gregorio Maranon | Calvo F.A.,Complutense University of Madrid | Sole C.V.,Hospital General Universitario Gregorio Maranon | Sole C.V.,Complutense University of Madrid | And 10 more authors.
Clinical and Translational Oncology | Year: 2013

The reality of intraoperative radiation therapy (IORT) practice is consistent with an efficient and highly precise radiation therapy technique to safely boost areas at risk for local recurrence. Long-term clinical experience has shown that IORT-containing multi-modality regimens appear to improve local disease control, if not survival in many diseases. Research with IORT is a multidisciplinary scenario that covers knowledge from radiation beam adapted development to advance molecular biology for bio-predictability of outcome. The technical parameters employed in IORT procedures are important information to be recorded for quality assurance and clinical results analysis. In addition, specific treatment planning systems for IORT procedures are available, to help in the treatment decision-making process. A systematic revision of opportunities for research and innovation in IORT is reported including radiation beam modulation, delivery, dosimetry and planning; infrastructure and treatment factors; experimental and clinical radiobiology; clinical trials, innovation and translational research development. © 2013 Federación de Sociedades Españolas de Oncología (FESEO).

Arias F.,Service of Radiation Oncology | Chicata V.,Service of Radiation Oncology | Garcia-Velloso M.J.,University of Navarra | Asin G.,Service of Radiation Oncology | And 10 more authors.
Clinical and Translational Oncology | Year: 2014

Results: FDG PET/CT changed the stage in 27 patients and had high impact on the management plan in 12 % of patients (detection of distant metastases in 6 patients and stage II in 2 patients). Intramodality changes were more frequent: FDG PET/CT altered the TNM stage in 18/72 (25 %) of patients, upstaging N stage in 90 % of patients with low impact.Conclusions: Initial FDG PET/CT staging not only improves stage but also affects the management plan in LAHNC patients.Objective: To determine the impact of initial FDG PET/CT staging on clinical stage and the management plan in patients with locally advanced head and neck cancer (LAHNC).Materials and methods: We retrospectively reviewed the records of 72 consecutive patients (2007–2010) staged with PET/CT and conventional CT with tumours of hypopharynx/larynx (26 patients, 36 %), oral cavity (17 patients, 24 %), oropharynx (16 patients, 22 %), nasopharynx (12 patients, 17 %), and others (2 %). The impact of PET/CT on management plans was considered high when PET/CT changed the planned treatment modality or treatment intent, and intramodality changes were considered as minor changes with low impact. © 2014, Federación de Sociedades Españolas de Oncología (FESEO).

Discover hidden collaborations